The renoprotective effects of SGLT2 inhibitors, particularly slowing the decline in eGFR, have been established in large trials involving patients with CKD with and without diabetes mellitus [[11], [12], [13], [14]]. Here, SLC5A2 is linked to chronic kidney disease.